SINTX Technologies Price Target Adjusted to $28.00, 'Buy' Rating Maintained

Ascendiant Capital analyst Edward Woo maintained a "Buy" rating for SINTX Technologies (SINT) with a revised price target of $28.00, a 6.67% decrease from the previous $30.00 target. Woo remains optimistic about the company's future prospects, despite the adjustment. The average target price for SINTX Technologies is $30.00, with an upside of 975.27% from the current price of $2.79. The estimated GF Value for SINTX Technologies in one year is $0.69, suggesting a 75.27% downside from the current price.

Ascendiant Capital analyst Edward Woo has maintained a "Buy" rating for SINTX Technologies (SINT), despite adjusting the price target to $28.00, a 6.67% decrease from the previous $30.00 target. This decision reflects a cautious yet optimistic view of the company's future prospects [1].

The average one-year price target for SINTX Technologies is $30.00, suggesting an impressive potential upside of 975.27% from the current price of $2.79. However, GuruFocus estimates a GF Value of $0.69 for SINTX Technologies in one year, indicating a significant downside of 75.27% from the current price [1].

Wall Street analysts' consensus remains largely positive, with 24 analysts setting an average one-year price target of $115.21 for Gilead Sciences Inc (GILD), suggesting a potential upside of 4.66% from the current share price of $110.08. This optimism is reflected in the "Outperform" consensus rating from 30 brokerage firms [2].

Despite the optimistic projections, GuruFocus' GF Value estimate for Gilead Sciences Inc (GILD) in one year is $83.69, predicting a potential downside of 23.97% from the current price of $110.08. This discrepancy highlights a cautious appraisal of the stock's fair trading value [2].

References:
[1] https://www.gurufocus.com/news/2898024/sintx-technologies-sint-rating-maintained-as-price-target-adjusted-sint-stock-news
[2] https://www.gurufocus.com/news/2899947/gilead-sciences-gild-reports-positive-results-for-trodelvy-combo-in-breast-cancer-study